Navigation Links
GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
Date:10/29/2010

n.  Treatment with migalastat HCl has been generally well-tolerated, with no drug-related serious adverse events. The most common adverse events were headache, arthralgia and diarrhea.

A Phase 3 study (Study 011) commenced in the second quarter of 2009 and treatment of the first patient began in the fourth quarter of 2009.  This ongoing study is a 6-month, randomized, double-blind trial comparing migalastat HCl to placebo in 60 subjects in approximately 40 investigational sites worldwide. The surrogate primary endpoint is the change in the amount of kidney interstitial capillary GL-3. Subjects being enrolled are Fabry patients who have never received enzyme replacement therapy (ERT), or who have not received ERT for at least 6 months, and who have a mutation responsive to migalastat HCl.

GSK and Amicus today provided an update to the enrollment timeline for Study 011.  Enrollment is now expected to be completed in the first quarter of 2011 and preliminary results are expected to be announced in the second half of 2011.

Furthermore, a separate Phase 3 study (Study 012) is expected to commence before year end.  The study will be an 18-month, randomized, open-label study comparing migalastat HCl to ERT in approximately 60 subjects. The primary outcome of efficacy will be renal function as measured by glomerular filtration rate (GFR).

About Fabry DiseaseFabry disease is an inherited lysosomal storage disorder caused by deficiency of an enzyme called alpha-galactosidase A (alpha-Gal A).  The role of alpha-Gal A within the body is to break down a complex lipid called globotriaosylceramide (GL-3).  Reduced or absent levels of alpha-Gal A activity leads to the accumulation of GL-3 in the affected tissues, including the central nervous system, heart, kidneys, and skin. This accumulation of GL-3 is believed to cause the various symptoms of Fabry disease, including pain, kidney failure, and increased risk of hear
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 Discovery Laboratories, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... at 8:30 a.m. Eastern Time on Tuesday August 11, ... 2015 second quarter financial results along with providing ... press release announcing the second quarter 2015 financial ...
(Date:8/3/2015)... Aug. 3, 2015 Diplomat Pharmacy, Inc. (NYSE: ... results for the quarter ended June 30, 2015. All comparisons, ... 2014. Second Quarter 2015 Highlights include: ... or $266 million , Total prescriptions dispensed of 234,000, ... versus 5.5% , Adjusted EBITDA of $22.7 million, an ...
(Date:8/3/2015)... CHESTNUT RIDGE, N.Y. , Aug. 3, 2015 /PRNewswire/ ... will host a conference call on Friday, August 7, ... of operations for the second quarter ended June 30, ... financial information available to the public in its filings ... certain other information available on its website by following ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... Jan. 18, 2011 BNY Mellon and The SSI Group, ... of the alliance between the two companies, SSI,s health care ... bill payment capabilities.   Under this agreement, health ... button to the screens they use in interacting with SSI,s ...
... AUSTIN, Texas, Jan. 18, 2011 Hanger Orthopedic Group, Inc. (NYSE: ... its results of operations for the quarter ended December 31, 2010, ... issue a press release announcing the results for the quarter ended ... February 9, 2011 after the close of the market. A conference ...
Cached Medicine Technology:The SSI Group to Provide Health Care Providers with BNY Mellon's Electronic Payment Solutions 2The SSI Group to Provide Health Care Providers with BNY Mellon's Electronic Payment Solutions 3Hanger Orthopedic Group, Inc. Announces Fourth Quarter 2010 Earnings Release Conference Call 2
(Date:8/3/2015)... ... ... They know every second counts. And when it comes to stroke, the ... best care in the nation. For the past two months, the stroke team led ... time in the country. During the months of June and July, it took the ...
(Date:8/3/2015)... ... 03, 2015 , ... Kantor & Kantor, LLP announced today ... client Rebecca Hamsher, deciding that in accordance with ERISA ( Employee Retirement Income ... treatment for bulimia, depression and other mental health problems. , According to the ...
(Date:8/3/2015)... ... 03, 2015 , ... Pitt Researchers to Monitor Resistance to ... School of Medicine are leading a five-year, $5 million initiative to monitor drug ... A cooperative agreement awarded by the U.S. Agency for International Development (USAID), will ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can ... costs. , Annually, more than 8.6 million adverse drug events are reported ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent ... for drugs, biologics and consumer health products, today welcomed the announcement by OPKO ... New Drug Application for a new treatment for chronic kidney disease (CKD) and ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... the Australian Institute of Health and Welfare (AIHW) has found ... heart attacks and cardiovascular disease at rates that are higher ... researchers have also reported in their study that people in ... hospital for the disease. The researchers have explained that their ...
... Roy Thayer’s underwent an emergency life saving operation by writing a ... was reported that Roy, 77, was warned that the long wait ... knew that there was no way he could afford to pay ... the operation at a private hospital, knowing fully well that by ...
... well into childhood long after children are weaned according ... revealed that breast-fed children cope better with stressful situations ... ,Dr Scott Montgomery, an epidemiologist at the Karolinska ... there is less of an association between parental divorce ...
... forum on HIV/AIDS for the UN will be among ... from Aug 13. // ,"Canada is eager ... disparities in access to HIV treatment throughout the world," ... the McGill University AIDS Center. ,The biennial ...
... cancer-fighting properties of tulsi, which is grown in many Indian ... 10 students at the University of Rajasthan.// ,"We arrived ... said Ashok Sharma, who heads the research project. ... IANS. The rats were first divided into two groups and ...
... sudden, worsening chest pain or a certain type of ... invasive treatment// rather than being treated conservatively, a new ... evidence suggests that an early invasive strategy is superior ... of the Centre for Research in Vascular Biology at ...
Cached Medicine News:Health News:Wily Old Man Undergoes A life Saving Operation With A Worthless Cheque 2Health News:Childhood Anxiety Reduced with Breast-feeding 2Health News:Indian to Conduct Workshop at Global AIDS Meet 2Health News:Emergency Heart Patients Do Better With Invasive Approach 2Health News:Emergency Heart Patients Do Better With Invasive Approach 3Health News:Emergency Heart Patients Do Better With Invasive Approach 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: